# NAD and Aging in the Research Literature | NAD+ Digest

> NAD and aging: tissue NAD+ falls with age as CD38 rises and the salvage pathway lags. A cited reading of the decline mechanism and the precursor research that aims to raise NAD+.

Tissue NAD+ falls with age. This scene reads why the decline happens, which enzymes drive it, and what precursor research has and has not shown.

## In plain English

As you get older, the amount of NAD+ (a fuel-handling helper molecule every cell uses to make energy) inside your tissues slowly drops. Part of the reason is an enzyme called CD38 that *burns* NAD+ and becomes more active with age, so the cell spends NAD+ faster than it can rebuild it. This page — about **NAD and aging** — walks through what the studies have shown about that decline, and why researchers test precursors (building blocks like NMN and NR) to try to push NAD+ back up. It describes findings only; it is not advice to take anything.

## Why tissue NAD+ falls with age

The age-related drop in NAD+ is not mainly a manufacturing failure — it is a consumption problem. CD38, an NAD-consuming ectoenzyme, rises with age and inflammation and is the principal driver of the fall in tissue NAD+ [2]. In mice, deleting CD38 preserves NAD+ levels and SIRT3 activity, protecting mitochondrial function and metabolic health into old age [2]. As NAD+ drops, sirtuins and PARPs — the other big consumers — compete harder for a shrinking pool, and nuclear-mitochondrial signaling can slip toward *pseudohypoxia*, a state in which the cell behaves as if starved of oxygen despite adequate supply [5].

Senescent cells make the problem self-reinforcing. The senescence-associated secretory phenotype (SASP) — the inflammatory signals aging cells release — drives CD38 expression in tissue macrophages, creating a feedback loop that depletes NAD+ further [14]. A 2024 review proposed pairing NAD-boosting strategies with senolytics (drugs that clear senescent cells) as a complementary approach in animal models [14]. This is mechanism, not a treatment claim.

## What precursor research has shown about the decline

If the decline is real, can raising NAD+ reverse its consequences? In animals, the signal is consistent. A 2024 critical review of NMN's anti-aging mechanisms identified four core pathways — cellular energy metabolism, apoptosis inhibition, immune modulation, and genomic stability — and documented NMN activating sirtuins while reducing CD38 and PARP-1 activity in aged tissue [15]. NMN supplementation reduced markers of cellular senescence in aged mice [14].

In humans the picture is narrower but not empty. NMN dose-dependently raised blood NAD+ over 60 days and improved walking distance in middle-aged adults [3], and 10 weeks of NMN improved muscle insulin sensitivity in prediabetic postmenopausal women [1]. What no human study shows is reversal of aging itself: a 2025 *Nature Metabolism* review concluded that age-related NAD+ decline has been confirmed in only a limited number of human studies and that human efficacy for clinical endpoints remains preliminary [13]. The strongest anti-aging data are still rodent data, and that gap is the honest center of this scene.

## Caution: context-dependence and the cancer question

Raising NAD+ is not uniformly benign in theory. NAMPT-driven NAD+ metabolism governs the proinflammatory SASP independently of growth arrest, and the authors of that work cautioned that NAD+ augmentation should be applied with precision in aging populations [8]. Separately, because NAD+ supports the metabolism of proliferating cells, a theoretical concern exists that boosting it could fuel existing cancers; NAD+ has dual, context-dependent roles in oncology, so caution is advised in cancer populations [13]. These are research caveats reported in the literature, not predictions about any individual, and this page makes no clinical recommendation.

---

One cold light on the NAD+ record — the coenzyme's age-related dimming and the NMN and NR precursor trials read scene by scene and cited to source, with no clinic behind the frame and nothing here prescribed, dispensed, or sold.